17,261 trials
Multiple Myeloma
Primary: Response Rates by Blade Criteria — 2; 5; 3; 2 Participants
Insulin Sensitivity
Primary: Effect of Eritoran on Muscle Insulin Sensitivity — 11.9; 10.2; 9.8 mg/kg/min — p=0.02
Phenylketonuria
Primary: Percent Change in Blood Phenylalanine — -13.71; -8.13; 48.75 Percent change in blood phenylalanine
Premature Ejaculation
Primary: Change From Baseline in Geometric Mean (GM) Intravaginal Ejaculatory Latency Time (IELT) Over the Treatment Assessment Period — 42.6; 39.7; 44.5; 29.2 Seconds
Pulmonary Arterial Hypertension
Primary: Pulmonary Vascular Resistance (PVR) — 6.7 woods unit
Recurrent Vulvovaginal Candidiasis
Primary: The Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes Through Week 48 of the Study in the Intent-to-treat Population. — 2; 3; 0; 2 Participants
Breast Cancer · Metastatic Triple Negative
Primary: Overall Response Rate in Unirradiated Lesions — 3; 0; 1; 8 Participants
Squamous Cell Carcinoma of the Head and Neck
Primary: Change From Baseline in 18F-EF5 Standardized Uptake Values (SUV) — 1.49 SUVmax
Small Cell Lung Cancer
Primary: Antitumour Activity Defined as Progression Free Survival (PFS) — 3.2 months
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 — 50.0; 64.6; 73.5; 81.6 percentage of participants — p=0.153
Muscular Atrophy, Spinal
Primary: Safety: Frequency of Adverse Events/Lab Abnormalities
Carcinoid Tumors · Pancreatic NET
Primary: Overall Radiographic Response Rate (ORR) — 0 Participants
Muscular Atrophy, Spinal
Primary: Efficacy: Functional Motor Testing, Including Gross Motor Function Measure (GMFM) and Timed Motor Tests
Obesity
Primary: Percentage Change From Baseline in Body Weight at Week 12 — -1.86; -2.84; -3.41; -3.80 Percent Change
Bladder Cancer
Primary: Pathologic Response Rate — 57 percentage of participants